{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:20Z","timestamp":1787003900410,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/tpj.2014.42","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T05:57:22Z","timestamp":1407823042000},"page":"172-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances"],"prefix":"10.1038","volume":"15","author":[{"given":"E","family":"Pe\u00f1as-Lled\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E G","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Jaussent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Blasco-Fontecilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Courtet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"LLerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"BFtpj201442_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/clpt.2009.216","volume":"88","author":"AL Zackrisson","year":"2010","unstructured":"Zackrisson AL, Lindblom B, Ahlner J . High frequency of occurrence of CYP2D6 gene duplication\/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354\u2013359.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201442_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/mp.2011.5","volume":"16","author":"EM Pe\u00f1as-Lled\u00f3","year":"2011","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Dorado P, Aguera Z, Gratacos M, Estivill X, Fernandez-Aranda F et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2011; 16: 691\u2013692.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201442_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/clpt.2010.239","volume":"89","author":"JC Stingl","year":"2011","unstructured":"Stingl JC, Viviani R . CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011; 89: 352\u2013353.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201442_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2217\/pgs.11.146","volume":"13","author":"EM Pe\u00f1as-Lled\u00f3","year":"2012","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-Garcia E, Llerena A . CYP2D6 and the severity of suicide attempts. Pharmacogenomics 2012; 13: 179\u2013184.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201442_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/14622416.10.1.17","volume":"10","author":"A Llerena","year":"2009","unstructured":"Llerena A, Dorado P, Pe\u00f1as-Lled\u00f3 EM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17\u201328.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201442_CR6","doi-asserted-by":"crossref","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Llerena A . CYP2D6 variation, behavior and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol 77: 673\u2013683.","DOI":"10.1111\/bcp.12227"},{"key":"BFtpj201442_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mp.2012.42","volume":"18","author":"JC Stingl","year":"2012","unstructured":"Stingl JC, Brockmoller J, Viviani R . Genetic variability of drug metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2012; 18: 273\u2013287.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201442_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.clpt.2003.12.015","volume":"75","author":"T Rau","year":"2004","unstructured":"Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75: 386\u2013393.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201442_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00228-003-0701-4","volume":"59","author":"C Kawanishi","year":"2004","unstructured":"Kawanishi C, Lundgren S, Agren H, Bertilsson L . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803\u2013807.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201442_CR10","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","volume":"71","author":"KW Lobello","year":"2010","unstructured":"Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010; 71: 1482\u20131487.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201442_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/pgs.09.168","volume":"11","author":"MH Tsai","year":"2010","unstructured":"Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11: 537\u2013546.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201442_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/mp.2012.91","volume":"18","author":"EM Pe\u00f1as-Lled\u00f3","year":"2013","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Trejo HD, Dorado P, Ortega A, Jung H, Alonso E et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry 2013; 18: 8\u20139.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201442_CR13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FTD.0b013e31817d6f5d","volume":"30","author":"M Gex-Fabry","year":"2008","unstructured":"Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474\u2013482.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201442_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/YIC.0b013e32832e5b0d","volume":"24","author":"A Serretti","year":"2009","unstructured":"Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009; 24: 250\u2013256.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFtpj201442_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FTD.0b013e31817721d6","volume":"30","author":"CJ Kobylecki","year":"2008","unstructured":"Kobylecki CJ, Hansen T, Timm S, Wang A, Jakobsen KD, S\u00f8rensen HJ et al. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. Ther Drug Monit 2008; 30: 265\u2013270.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201442_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00406-012-0375-y","volume":"263","author":"P H\u00f6fer","year":"2013","unstructured":"H\u00f6fer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA et al. The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2013; 263: 385\u2013391.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFtpj201442_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00406-013-0402-7","volume":"263","author":"EM Pe\u00f1as-Lled\u00f3","year":"2013","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Naranjo ME, Llerena A . Impact of cytochrome P450 genes on suicide attempt and risk. Eur Arch Psychiatry Clin Neurosci 2013; 263: 703\u2013704.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFtpj201442_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/tpj.2010.85","volume":"12","author":"A Llerena","year":"2012","unstructured":"Llerena A, Dorado P, Ram\u00edrez R, Gonz\u00e1lez I, Alvarez M, Pe\u00f1as-Lled\u00f3 EM et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics 2012; 12: 176\u2013183.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201442_CR19","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I . Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284\u2013295.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201442_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2012.45","volume":"13","author":"SC Sim","year":"2013","unstructured":"Sim SC, Kacevska M, Ingelman-Sundberg M . Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics 2013; 13: 1\u201311.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201442_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/mp.2013.89","volume":"19","author":"A Persson","year":"2013","unstructured":"Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M . Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 2013; 19: 733\u2013741.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201442_CR22","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ajmg.b.31081","volume":"153B","author":"SC Sim","year":"2010","unstructured":"Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL et al. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1160\u20131166.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201442_CR23","first-page":"45","volume-title":"The Prediction of Suicide","author":"AT Beck","year":"1974","unstructured":"Beck AT, Schuyler D, Herman I . Development of Suicidal Intent Scales. In: Beck AT (ed). The Prediction of Suicide. Charles Press: Pennsylvania, PA, USA, 1974, pp 45\u201356."},{"key":"BFtpj201442_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2144\/000112044","volume":"39","author":"P Dorado","year":"2005","unstructured":"Dorado P, C\u00e1ceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571\u2013574.","journal-title":"Biotechniques"},{"key":"BFtpj201442_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00228-010-0864-8","volume":"66","author":"RS Pedersen","year":"2010","unstructured":"Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010; 66: 1199\u20131205.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201442_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 34\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201442_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","volume":"21","author":"DA Mrazek","year":"2011","unstructured":"Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011; 21: 1\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201442_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2217\/bmm.11.32","volume":"5","author":"D Villagra","year":"2011","unstructured":"Villagra D, Goethe J, Schwartz HI, Szarek B, Kocherla M, Gorowski K et al. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomark Med 2011; 5: 427\u2013438.","journal-title":"Biomark Med"},{"key":"BFtpj201442_CR29","doi-asserted-by":"crossref","unstructured":"Blasco-Fontecilla H, Pe\u00f1as-Lled\u00f3 E, Vaquero-Lorenzo C, Dorado P, Saiz-Ruiz J, Llerena A et al. CYP2D6 polymorphism and mental and personality disorders in suicide attempters. J Personal Disord advance online publication, 11 February 2013 (e-pub ahead of print).","DOI":"10.1521\/pedi_2013_27_080"},{"key":"BFtpj201442_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.mp.4002057","volume":"13","author":"PW Schenk","year":"2008","unstructured":"Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13: 597\u2013605.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201442_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881111414451","volume":"26","author":"P Huezo-Diaz","year":"2012","unstructured":"Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2012; 26: 398\u2013407.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201442_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/tpj.2010.39","volume":"11","author":"A de Vos","year":"2011","unstructured":"de Vos A, van der Weide J, Loovers HM . Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011; 11: 359\u2013367.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201442_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","volume":"83","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E . Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008a; 83: 322\u2013327.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201442_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","volume":"6","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Hermann M, Refsum H, Molden E . Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008b; 6: 1181\u20131188.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201442_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/tpj.2009.50","volume":"10","author":"PW Schenk","year":"2010","unstructured":"Schenk PW, van Vliet M, Mathot RA, van Gelder T, Vulto AG, van Fessem MA et al. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J 2010; 10: 219\u2013225.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201442_CR36","doi-asserted-by":"crossref","unstructured":"Lopez-Castroman J, Jaussent I, Beziat S, Genty C, Olie E, de Leon-Martinez V et al. Suicidal phenotypes associated withfamily history of suicidal behavior and early traumatic experiences. J Affect Disord 142: 193\u2013199.","DOI":"10.1016\/j.jad.2012.04.025"},{"key":"BFtpj201442_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/ajp.156.2.181","volume":"156","author":"JJ Mann","year":"1999","unstructured":"Mann JJ, Waternaux C, Haas GL, Malone KM . Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psych 1999; 156: 181\u20131899.","journal-title":"Am J Psych"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201442","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:16:21Z","timestamp":1717208181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFtpj201442"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2014.42","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]},"assertion":[{"value":"11 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Blasco-Fontecilla has received lecture fees from Eli Lilly, AB-Biotics and Shire. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}